Sep 13, 2022 / 12:00PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hey, everyone. Good morning. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst here at Morgan Stanley. It's my pleasure to host Ken Knight, CEO of Invitae here. And again, thanks for joining us. Before we get started, I just have to read the research disclosures. For important disclosures, please see the Morgan Stanley website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo with that, Ken, thanks again for joining us. Maybe just to set the stage, I mean, obviously, it's been a very eventful year for Invitae. Can you talk about sort of your key priorities heading into year-end and into '23 after the restructuring? And what are you most looking forward to over the next 12 months?
Kenneth D. Knight - Invitae Corporation - President, CEO & Director
Well,